Verastem, Inc. (VSTM) stock

VSTMNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 3/30

$8.18−0.26 (-3.08%)

Close on Nov 13, 2026Market cap $740.81MP/E –Yield –

Verastem ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Verastem's ebitda for the twelve months ending Dec 31, 2016 was -$36.33M. For fiscal 2016 it was -$36.33M. The highest annual figure on record is -$13.62M in fiscal 2011.

Annual ebitda

Period	Period end	Value	Change
FY2016	Dec 31, 2016	-$36.33M	–
FY2015	Dec 31, 2015	-$57.45M	–
FY2014	Dec 31, 2014	-$53.18M	–
FY2013	Dec 31, 2013	-$41.17M	–
FY2012	Dec 31, 2012	-$32.02M	–
FY2011	Dec 31, 2011	-$13.62M	–

Quarterly ebitda

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q4 FY2016	Dec 31, 2016	-$11.65M	–
Q3 FY2016	Sep 30, 2016	-$7.90M	–

Where these numbers come from

Parsed from the XBRL in Verastem's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-12 reverse split on Jun 1, 2023
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is VSTM.

Compare: VSTM vs KURA · VSTM vs RCUS · VSTM vs NUVB · VSTM vs GOSS · VSTM vs RIGL

Operating margin-193.7% · median -140.0%

Net margin-178.4% · median -159.5%

Company	Revenue	Growth
RIGL	$288.21M	+2.2%
NUVB	$201.73M	+654.2%
VSTM	$100.30M	–
RCUS	$100.00M	-58.3%
KURA	$79.31M	–
GOSS	$78.42M	+78.0%

Company

Next earnings (est.): Feb 3, 2027, before open
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 102
Held by institutions: 100.0%
Auditor: Ernst & Young LLP
SEC CIK: 1526119

Advertisement
300 × 250

See a number that looks wrong?